Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis (Q40498114)

21 September 2017

Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis (English)

1 reference

21 September 2017

0 references

multiple drug resistance

1 reference

Robert S Wallis

1

1 reference

PubMed ID

26409278

21 September 2017

Thomas Peppard

series ordinal

2

1 reference

PubMed ID

26409278

21 September 2017

language of work or name

English

0 references

publication date

1 October 2015

1 reference

Clinical Infectious Diseases

21 September 2017

1 reference

21 September 2017

61Suppl 3

1 reference

21 September 2017

S160-3

1 reference

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

21 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

A four-month gatifloxacin-containing regimen for treating tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Validation of analytic methods for biomarkers used in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

Prioritized current unmet needs for antibacterial therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV612

21 January 2018

Identifiers

DOI

10.1093/CID/CIV612

1 reference

21 September 2017

1 reference

PubMed ID

26409278